Please assess the completion status of the following clinical trial:

Trial Title: Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent before any assessment~* Patients with type 1 or type 2 diabetes mellitus and HbA1c of ≤10% at screening~* Medication for the management of diabetes stable within 3 months prior to randomization and is expected to remain stable during the course of the study~Exclusion Criteria:~* Active proliferative diabetic retinopathy in the study eye~* Active intraocular or periocular infection or active intraocular inflammation in study eye~* Uncontrolled glaucoma in the study eye defined as intraocular pressure (IOP) \> 25 millimeters mercury (mmHg)~* Previous treatment with anti-VEGF drugs or investigational drugs in the study eye~* Stroke or myocardial infarction during the 6-month period prior to baseline~* Uncontrolled blood pressure defined as a systolic value ≥160 mmHg or diastolic value ≥100 mmHg~Other protocol-specified inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Brolucizumab 3 mg (Type: EXPERIMENTAL): Brolucizumab 3 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule.~To fulfil the double-masking requirement, each investigational site had masked and unmasked staff. The investigator who performed the injection was unmasked to the treatments as were any other site personnel who had been delegated responsibility for working with the Investigational Product (IP).
- Brolucizumab 6 mg (Type: EXPERIMENTAL): Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule.~To fulfil the double-masking requirement, each investigational site had masked and unmasked staff. The investigator who performed the injection was unmasked to the treatments as were any other site personnel who had been delegated responsibility for working with the Investigational Product (IP).
- Aflibercept 2 mg (Type: ACTIVE_COMPARATOR): Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks.~To fulfil the double-masking requirement, each investigational site had masked and unmasked staff. The investigator who performed the injection was unmasked to the treatments as were any other site personnel who had been delegated responsibility for working with the Investigational Product (IP).

Based on this trial design, predict the completion outcome and termination type (if applicable).